Please login to the form below

Not currently logged in
Email:
Password:

Takeda UK launches new Prostap format

Takeda has launched a simpler, more efficient presentation of its prostate cancer and endometriosis treatment

Takeda UK has launched its prostate cancer and endometriosis and uterine fibroids treatment Prostap DCS (leuprorelin acetate) in a dual chamber pre-filled syringe.

The company said that the latest syringe offers a simplified, intuitive and efficient delivery system compared to the original Prostap vial and syringe mechanism.

Raj Persad, consultant urologist, Bristol Royal Infirmary and Southmead Hospital commented "Leuprorelin acetate has proved to be an efficacious treatment for prostate cancer for many years. An accurate and user-friendly delivery system can only be a positive step forward, particularly as administration is more efficient and therefore saves time. This can result in a better standard of care for patients as more time is spent providing much needed support and advice."

Prostap DCS delivers the same active ingredient and will be available in the same doses as existing presentations: one-month Prostap SR DCS (depot injection 3.75mg) and three-month Prostap 3 DCS (depot injection 11.25mg).

Prostap will not be available after October 2011.

6th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics